55464-76-1

Usage

Properties

1. Chemical compound
2. Used in the production of polymers
3. Crosslinking agent in coatings and adhesives
4. Colorless liquid
5. Sharp, pungent odor
6. Highly flammable
7. Used in synthesis of pharmaceuticals
8. Monomer in production of resins and plastics
9. Reactive chemical
10. Can cause irritation to skin, eyes, and respiratory system
11. Should be handled with care
12. Avoid contact with oxidizing agents
13. Store in a cool, well-ventilated area
14. Versatile with wide range of industrial applications

Specific content

Primarily used in production of polymers and as a crosslinking agent in coatings and adhesives
Used in synthesis of pharmaceuticals and as a monomer in production of resins and plastics
Should be handled with care as it can cause irritation to skin, eyes, and respiratory system
Important to avoid contact with oxidizing agents and store in cool, well-ventilated area
Highly flammable colorless liquid with sharp, pungent odor

InChI:InChI=1/C7H8O4/c1-2-5-11-7(10)4-3-6(8)9/h2-4H,1,5H2,(H,8,9)/b4-3+

Upstream product

• 2807-54-7 diallyl fumarate 
• 110-17-8 (2E)-but-2-enedioic acid 
• 108-31-6 maleic anhydride 
• 107-18-6 allyl alcohol 

Relevant academic research and scientific papers

DNA-TEMPLATED MACROCYCLE LIBRARY

The present invention provides nucleic acid templates (e.g., including orthogonal codon sets (e.g., codons from orthogonal codon sets depicted in Tables 5 or 7)) for DNA-templated methods of synthesizing, selecting, and amplifying compounds (e.g., polymers and/or small molecules) described herein. Also provided are novel macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, libraries, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing a disease (e.g., a disease associated with aberrant enzyme activity (e.g., aberrant protease and/or kinase activity (e.g., aberrant IDE activity)), impaired insulin signaling, or insulin resistance in a subject (e.g., a subject having diabetes). Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit aberrant protease activity (e.g., aberrant IDE activity).

Process for the preparation of fumaric acid monoesters

Fumaric acid monoesters can be prepared by introducing a hydroxyl compound at a rate corresponding to the progress of the reaction into a solution or a melt of maleic anhydride, which may optionally be substituted, if appropriate in the presence of a cis-trans catalyst. New fumaric acid monoesters can be formed by the process.